Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Highlighting the event is the immersive simulation, “Seeing Beyond the Ordinary and Repairing Damages,” led by world-renowned ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

It's a daycare procedure and doesn't require hospitalisation. However, it is an expensive treatment. Will my health insurance ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

Striking a balance between innovation and responsibility is imperative. By prioritizing transparency, adhering to robust ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.